Sign In
Buy NVCT
$9.31
-0.200 (-2.10%)
At Close: Jun 03, 2026
Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights
08:00am, Tuesday, 05'th Mar 2024
FORT LEE, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovati
Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
08:32am, Friday, 09'th Feb 2024
Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
08:00am, Friday, 09'th Feb 2024
Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative
Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
08:00am, Wednesday, 03'rd Jan 2024
Fort Lee, NJ, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative
Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights
08:00am, Wednesday, 08'th Nov 2023
FORT LEE, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovativ
Down -36.49% in 4 Weeks, Here's Why You Should You Buy the Dip in Nuvectis Pharma, Inc. (NVCT)
11:18am, Monday, 16'th Oct 2023
The heavy selling pressure might have exhausted for Nuvectis Pharma, Inc. (NVCT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Stre
Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation
07:30pm, Monday, 25'th Sep 2023
Fort Lee, NJ, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative
Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900
08:00am, Thursday, 21'st Sep 2023
Fort Lee, NJ, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative
Nuvectis: Early Stage Company That's Low On Cash
08:03am, Wednesday, 06'th Sep 2023
Nuvectis is developing precision medicines for cancer patients, with lead asset NXP800 targeting ARID1a-mutated ovarian cancer. Preclinical trials have shown strong antitumor activity of NXP800, inclu
Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900
08:00am, Wednesday, 06'th Sep 2023
Virtual Event to be held on Thursday, September 14, 2023 at 10:00 a.m. ET Virtual Event to be held on Thursday, September 14, 2023 at 10:00 a.m. ET
